Figure 4.

Knockdown of YAP enhances sensitivity of hepatocellular carcinoma cells to CDDP through modulating phosphoinositide 3-kinase/AKT signaling. (A) SMMC-7721 cells were transfected with control siRNA or siRNA against YAP. Then, 48 h later proteins were extracted and subjected to western blot analysis using antibodies against AKT and p-AKT. (B) Untransfected and siRNA-transfected cells were seeded at 4×10³ cells/well in 96-well plates and treated with different concentrations of CDPP for 48 h. Then, cell viability was determined using an MTT assay. (C) Western blot analysis of AKT and p-AKT in SMMC-7721 cells transfected with control siRNA or siYAP following treatment with CDDP for 48 h. (D) SMMC-7721 cells transfected with control siRNA or siYAP were treated with 10 µM LY294002 for 12 h prior to being treated with CDDP. Then, cell viability was determined using an MTT assay. *P<0.05; **P<0.01. YAP, Yes-associated protein; CDDP, cisplatin; siRNA/si, small interferring RNA; AKT, AKT serine/threonine kinase; p-, phosphorylated; siCtr, control siRNA; siYAP, siRNA against YAP; Untrans, untransfected.